- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05829187
Momordica Charantia and Dihydroartemisinin-piperaquined-primaquine for Uncomplicated Plasmodium Falciparum Malaria Patients in Southwest Sumba Regency (MCHUPF)
Effectiveness of Momordica Charantia Extract Compared to the Standard Antimalarial Drug Combination Dihydroartemisinin Piperaquine-primaquine in Patients With Uncomplicated Falciparum Malaria, in Sumba Barat Daya District of Indonesia
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The Study was conducted in Kori Primary Health Cender, Sumba Barat Daya District, East Nusa Tenggara Province on Sumba Island.
The study subject received either 3 day of dihydroartemisinin-piperaquine and primaquine 1 day on first day (DHP+PQ) or extract of bitter melon (Momordica charantia/MC) + Placebo 1 day on first day according to their body weight.
Patients with fever or history of fever within the past 24 hours were screened by microscopic examination of giemsa stained tihick blood films to detect Plasmodium falciparum infection.
All Patient were allocated by single blind randomization to receive DHP (on day 0 to day 2)+PQ (on day 0 only) or extract of bitter melon (Momordica charantia/MC) (on day 0 to day 2)+placebo (on day 0 only). The procedures of drug administration in the study were as follows:
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
East Nusa Tenggara
-
Tambolaka, East Nusa Tenggara, Indonesia, 87255
- Kori Puskesmas
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:-
- Age ≥ 18 years old male or female up to 60 years old
- Single Plasmodium falciparum infection based on microscopic examination.
- Count the parasites for Plasmodium falciparum at least 2 large visual field asexual parasites (LPB) by examining 15 LPB
- Density of parasites 1000-100,000/micro liter
- Has no history of uncontrolled comorbidities
- History of fever in the last 24 hours for falciparum malaria
- Not taking other antimalarial drugs in the last 2 weeks.
- Have no previous history of malaria.
- Willing to come to the health facility according to the specified follow-up schedule.
- Willing to participate in research and established procedures.
- There is no history of allergy to antimalarial drugs.
Exclusion Criteria:
- Signs of general weakness, or decreased consciousness or recurrent seizures or circulation failure or pulmonary edema or signs of anemia or yellow body and slightly red urine.
- If the examination results show mixed Plasmodium and non-Plasmodium falciparum.
- Has a history of severe liver, kidney and heart dysfunction, bradycardia and heart rhythm disturbances.
- Does not control regularly according to the research schedule
- Pregnant and lactating women
- There are signs of severe malaria
- Patients with chronic diseases, for example: heart, kidney, liver, HIV.
- Mixed infection.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Dihydro artemisinin Piperakuin (Fixed Dose Combination) and Primaquine
Fixed Dose Combination content in the form of 40 mg dihydroartemisinin and 320 mg piperaquine administered for 3 days with a dose of dihydroartemisinin 2-4 mg/Kg body weight, piperaquine at a dose of 16-32 mg/Kg body weight in the form of a combination set out in the table based on body weight and age.
Primaquine dose of 0.25 mg/Kg body weight is given only on the first day.
Dihydroartemisinin-piperaquine was local product by PT Mersi Pharmaceuticals, batch No 220610, produced on Jun/22 and expiring on Jun/24.
primaquine was local product by PT Phapros Indonesia, Batch No 56386001, produced on Jan/22 and expiring date jan/25.
|
dihidroartemisinin dose of 2-4 mg/Kg Body weight taken for 3 days
Other Names:
piperaquine at a dose of 16-32 mg/Kg body weight taken for 3 days
Other Names:
Primaquine dose 0.25 mg/kg body weight given to uncomplicated Plasmodium falciparum patients on the first day only
Other Names:
|
Experimental: Extract Capsul Momordica Charantia
Momordica Charantia 325 mg in 500 mg capsules is given to patients with uncomplicated plasmodium falsiparum malaria as one capsule per day for three days for body weight less than 60 kg.
Patients with a body weight of more than 60 kg are given two capsules per day for three days.
|
Momordica charantia extract capsules at a dose of 325 mg were given to patients for 3 days
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
development of sexual and asexual stages of Plasmodium falciparum
Time Frame: 28 day post treatment
|
Finger prick blood samples are collected for malaria blood smear.
Thick and thin blood smear were stained with 3% giemsa solution for 45 minutes and were read under binocular microscope with 1,000x magnification
|
28 day post treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Parasite clearence times
Time Frame: 28-days
|
parasite reduction ratio
|
28-days
|
Fever clearence time
Time Frame: 28 days
|
time taken for the axilla temperature to fall below 37.5°C in patients who were febrile at inclusion
|
28 days
|
Number of adverse event
Time Frame: 28 days
|
28 days
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Measure imunomodulator Effect
Time Frame: 1x24 hour before and after treatment
|
Measuring the immunomodulatory effect by measuring the levels of TNF alpha and interferon gamma cytokines before and after the treatment intervention 1 x 24 hours
|
1x24 hour before and after treatment
|
Collaborators and Investigators
Publications and helpful links
General Publications
- Abdillah S, Tambunan RM, Sinaga YM, Farida Y. Ethno-botanical survey of plants used in the traditional treatment of malaria in Sei Kepayang, Asahan of North Sumatera. Asian Pac J Trop Med. 2014 Sep;7S1:S104-7. doi: 10.1016/S1995-7645(14)60213-3.
- Sutanto I, Suprijanto S, Kosasih A, Dahlan MS, Syafruddin D, Kusriastuti R, Hawley WA, Lobo NF, Ter Kuile FO. The effect of primaquine on gametocyte development and clearance in the treatment of uncomplicated falciparum malaria with dihydroartemisinin-piperaquine in South sumatra, Western indonesia: an open-label, randomized, controlled trial. Clin Infect Dis. 2013 Mar;56(5):685-93. doi: 10.1093/cid/cis959. Epub 2012 Nov 21.
- Jia S, Shen M, Zhang F, Xie J. Recent Advances in Momordica charantia: Functional Components and Biological Activities. Int J Mol Sci. 2017 Nov 28;18(12):2555. doi: 10.3390/ijms18122555.
- Chen F, Huang G, Yang Z, Hou Y. Antioxidant activity of Momordica charantia polysaccharide and its derivatives. Int J Biol Macromol. 2019 Oct 1;138:673-680. doi: 10.1016/j.ijbiomac.2019.07.129. Epub 2019 Jul 22.
- Wang S, Liu Q, Zeng T, Zhan J, Zhao H, Ho CT, Xiao Y, Li S. Immunomodulatory effects and associated mechanisms of Momordica charantia and its phytochemicals. Food Funct. 2022 Nov 28;13(23):11986-11998. doi: 10.1039/d2fo02096c.
- Nelwan EJ, Ekawati LL, Tjahjono B, Setiabudy R, Sutanto I, Chand K, Ekasari T, Djoko D, Basri H, Taylor WR, Duparc S, Subekti D, Elyazar I, Noviyanti R, Sudoyo H, Baird JK. Randomized trial of primaquine hypnozoitocidal efficacy when administered with artemisinin-combined blood schizontocides for radical cure of Plasmodium vivax in Indonesia. BMC Med. 2015 Dec 11;13:294. doi: 10.1186/s12916-015-0535-9.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- B-056/FI2/KEPK/TL.00/10/2022
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Uncomplicated Plasmodium Falciparum
-
Novartis PharmaceuticalsRecruitingUncomplicated Plasmodium Falciparum MalariaCôte D'Ivoire, Kenya, Ghana, Uganda
-
Medicines for Malaria VentureCompletedUncomplicated Plasmodium Falciparum MalariaUganda, Benin, Burkina Faso, Congo, The Democratic Republic of the, Gabon, Mozambique, Vietnam
-
Karolinska University HospitalMuhimbili University of Health and Allied SciencesCompletedUncomplicated Plasmodium Falciparum MalariaTanzania
-
University of OxfordNot yet recruitingUncomplicated Plasmodium Falciparum Malaria
-
Ministry of Public Health, Democratic Republic...Centers for Disease Control and Prevention; Global FundActive, not recruitingUncomplicated Plasmodium Falciparum MalariaCongo, The Democratic Republic of the
-
Medicines for Malaria VentureShin Poong Pharmaceuticals; Institute of Tropical Medicine, University of TuebingenCompletedPyronaridine and Artesunate (3:1) in Children With Acute Uncomplicated Plasmodium Falciparum MalariaUncomplicated Plasmodium Falciparum MalariaGabon
-
Muhimbili University of Health and Allied SciencesUppsala University; The Swedish Research CouncilNot yet recruitingUncomplicated Plasmodium Falciparum MalariaTanzania
-
Novartis PharmaceuticalsEuropean and Developing Countries Clinical Trials Partnership (EDCTP)RecruitingUncomplicated Plasmodium Falciparum MalariaBurkina Faso, Mali, Gabon
-
David SaundersNational Centre for Parasitology, Entomology and Malaria Control, Cambodia; Royal Cambodian Armed Forces and other collaboratorsSuspendedUncomplicated Plasmodium Falciparum MalariaCambodia
-
Centers for Disease Control and PreventionMinistry of Health, LiberiaCompletedMalaria | Plasmodium Falciparum | Uncomplicated MalariaLiberia
Clinical Trials on Dihydroartemisinin
-
London School of Hygiene and Tropical MedicineMedical Research Council Unit, The GambiaTerminated
-
University of OxfordMahidol Oxford Tropical Medicine Research UnitCompleted
-
Indonesia UniversityCompleted
-
Liverpool School of Tropical MedicineThe Research Council of Norway; Makerere University; Kenya Medical Research InstituteCompleted
-
Shanghai Zhongshan HospitalRecruiting
-
Medical University of South CarolinaCompletedAlcohol Dependence | Bipolar DisorderUnited States
-
Grant Dorsey, M.D, Ph.D.Eunice Kennedy Shriver National Institute of Child Health and Human Development...Completed
-
University of California, San FranciscoMahidol University; Holley-Cotec Pharmaceuticals Co., LTD.Completed
-
National Institute for Medical Research, TanzaniaNational Malaria Control Program, TanzaniaActive, not recruiting
-
Richard MwaisweloNational Institute for Medical Research, Tanzania; Muhimbili University of... and other collaboratorsCompletedMalaria | Chemoprophylaxis | Underfive ChildrenTanzania